PROTACs
PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.
PROTACs Isoform Specific Products
-
PROTACs Related Products (1398)
Related Products (1398)
-
Antibodies (1)
-
PROTACs Isoform Comparison
-
Gal-ARV-771
0 ImagesCat. No.: HY-158331CAS No.: 3055593-64-8Gal-ARV-771 is a galactose-modified derivative of ARV-771 (HY-100972). Gal-ARV-771 is activated in cells expressing SA-β-Gal, thereby releasing ARV-771. Gal-ARV-771 selectively induces Apoptosis. ARV-771 is a BET PROTAC degrader. Gal-ARV-771 can be used in the research of lung adenocarcinoma (Gal+linker: Gal-PAB (HY-188142); PROTAC: ARV-771 (HY-100972)).
-
PROTAC BTK Degrader-4
0 ImagesCat. No.: HY-128408CAS No.: 2893795-12-3PROTAC BTK Degrader-4 (compound 15) is a potent PROTAC Bruton's tyrosine kinases (BTK) degrader (DC50 < 100 nM) with little immunomodulatory imide drug (IMiD) activity (DC50 = 0.345 μM, Dmax = 27.4%). PROTAC BTK Degrader-4 can be used for cancers, autoimmune diseases, and inflammatory diseases that are mediated by BTK.
-
PROTAC BRM/BRG1 degrader-3
0 ImagesCat. No.: HY-168251CAS No.: 2933125-05-2PROTAC BRM/BRG1 degrader-3 is a BRM/BRG1 PROTAC degrader, exhibiting a DC50 of less than 1 nM for BRM degradation and a DC50 of greater than 1 nM for BRG1 degradation in SW1573 cells. PROTAC BRM/BRG1 degrader-3 shows moderate inhibitory activity against CYP2D6 and hERG. PROTAC BRM/BRG1 degrader-3 inhibits cancer cell proliferation and tumor tissue growth, and exhibits favorable metabolic stability in liver microsomes. PROTAC BRM/BRG1 degrader-3 can be used in non-small cell lung cancer-related research.
-
PROTAC SOS1 degrader-3
0 ImagesCat. No.: HY-152145CAS No.: 3029320-99-5PROTAC SOS1 degrader-3 is a PROTAC degrader targeting SOS1, which induces the targeted degradation of SOS1 via the ubiquitin-proteasome system, with DC50 values ranging from 0.19 μM to 0.75 μM in multiple distinct colorectal cancer cell lines. PROTAC SOS1 degrader-3 inhibits the phosphorylation of AKT and ERK. PROTAC SOS1 degrader-3 induces apoptosis and morphological changes in KRAS-mutant colorectal cancer organoids. PROTAC SOS1 degrader-3 can be applied in studies related to kras-mutant colorectal cancer.
-
PROTAC BRM/BRG1 degrader-2
0 ImagesCat. No.: HY-168247CAS No.: 2933124-32-2
-
PROTAC GDI2 Degrader-1
0 ImagesCat. No.: HY-156244PROTAC GDI2 Degrader-1 is a GDI2 PROTAC degrader with a DC50 value of 1.48 μM and a Kd value of 23.9 μM. PROTAC GDI2 Degrader-1 triggers paraptosis in tumor cells via endoplasmic reticulum expansion and fusion, endoplasmic reticulum stress, unfolded protein response, and cytoplasmic vacuolization. PROTAC GDI2 Degrader-1 exhibits significant in vivo anti-tumor activity in pancreatic cancer xenograft models. PROTAC GDI2 Degrader-1 can be used for research related to pancreatic cancer.
-
PROTAC α-synuclein degrader 1
0 ImagesCat. No.: HY-135999CAS No.: 2412273-73-3PROTAC α-synuclein degrader 1 is a α-synuclein PROTAC degrader that can recruit VHL. PROTAC α-synuclein degrader 1 induces ubiquitination and degradation of α-synuclein, and is applicable to researches on Parkinson's disease, Alzheimer's disease, dementia with Lewy bodies, multiple system atrophy, etc.
-
PROTAC TG2 Degrader-3
0 ImagesCat. No.: HY-181732CAS No.: 3054388-18-7PROTAC TG2 Degrader-3 is a TG2 (TGM2) PROTAC degrader. PROTAC TG2 Degrader-3 inhibits the adhesion and migration of ovarian cancer cells. PROTAC TG2 Degrader-3 can be used for the research of ovarian cancer.
-
SGI-1776-VHL-02
0 ImagesCat. No.: HY-186146CAS No.: 3013618-84-0SGI-1776-VHL-02 is a stereoselective PIM PROTAC degrader. SGI-1776-VHL-02 promotes the ubiquitination and degradation of PIM1, PIM2 and PIM3. SGI-1776-VHL-02 downregulates c-myc protein levels, induces Apoptosis. SGI-1776-VHL-02 has anti-cancer activity against prostate cancer. SGI-1776-VHL-02 can be used in studies related to prostate cancer.
-
SN38-(PEG)2-Pom-α
0 ImagesCat. No.: HY-180555SN38-(PEG)2-Pom-α is a selective PROTAC RPL15 degrader. SN38-(PEG)2-Pom-α induces ubiquitin-mediated degradation of RPL15 without affecting TOP1. SN38-(PEG)2-Pom-α induces damage-associated molecular pattern (DAMP) secretion from cancer cells, which activated cGAS-STING signaling in dendritic cells. SN38-(PEG)2-Pom-α enhances anti-PD-1 immunotherapy in a murine melanoma tumor model expressing human CRBN. SN38-(PEG)2-Pom-α can be used for melanoma research.
-
PROTAC BRAF-V600E degrader-2
0 ImagesCat. No.: HY-137488CAS No.: 2417296-82-1PROTAC BRAF-V600E degrader-2 is a PROTAC degrader targeting BRAF-V600E. The Kd values of PROTAC BRAF-V600E degrader-2 for BRAF and BRAF-V600E are 14.4 nM and 9 nM, respectively. PROTAC BRAF-V600E degrader-2 selectively degrades BRAF-V600E but does not degrade wild-type BRAF. PROTAC BRAF-V600E degrader-2 inhibits the MEK/ERK kinase cascade and suppresses the growth of melanoma cells. PROTAC BRAF-V600E degrader-2 can be used in studies related to melanoma and colon cancer.
-
ZXH-4-137
0 ImagesCat. No.: HY-132862CAS No.: 2711006-74-3ZXH-4-137 is a CRBN PROTAC degrader. ZXH-4-137 brings CRBN and VHL E3 ligase into proximity, induces CRBN ubiquitination and proteasomal degradation, and exhibits high selectivity for CRBN. ZXH-4-137 blocks the degradation of CRBN-dependent target proteins such as GSPT1 and CDK9. ZXH-4-137 serves as a chemical knockdown tool compound for investigating CRBN-dependent biological processes.
-
PROTAC RET Degrader 1
0 ImagesCat. No.: HY-178964CAS No.: 2760847-82-1PROTAC RET Degrader 1 is an orally active, blood-brain barrier-penetrant RET PROTAC degrader with a DC50 of 1.7 nM. PROTAC RET Degrader 1 binds to CRBN and forms a ternary complex with RET, mediating proteasomal degradation of RET, while also selectively mediating the degradation of SALL4. PROTAC RET Degrader 1 inhibits the RET signaling pathway, hERG channel activity, and Cyp3A4 enzyme activity; it suppresses cancer cell growth and induces tumor regression. PROTAC RET Degrader 1 can be used in research related to RET-driven cancers.
-
MS5033
0 ImagesCat. No.: HY-143882CAS No.: 2376137-29-8MS5033 is a CRBN-recruiting PROTAC degrader that targets AKT1. The IC50 values of MS5033 against human AKT range from 1.3 nM to 798 nM, with Kd values ranging from 4.8 nM to 160 nM. MS5033 inhibits downstream AKT signaling pathways, including the phosphorylation of PRAS40, thereby suppressing cancer cell proliferation and colony formation and inducing cancer cell apoptosis. MS5033 can be used in research on glioma, prostate cancer, triple-negative breast cancer, breast cancer and solid tumors.
-
R4VPL3-1
0 ImagesCat. No.: HY-184506R4VPL3-1 is a PROTAC-like degrader that simultaneously targets RNF4 and VHL, and also acts as a ferroptosis inducer. R4VPL3-1 induces iron-dependent lipid peroxidation and ferroptosis-mediated rapid cell death in cancer cells. R4VPL3-1 is applicable to research on human melanoma, human cutaneous squamous cell carcinoma, metastatic human sarcoma, malignant peripheral nerve sheath tumor, pigmented villonodular synovitis, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and lung adenocarcinoma.
-
PROTAC EZH2 Degrader-19
0 ImagesCat. No.: HY-181320CAS No.: 2653338-65-7PROTAC EZH2 Degrader-19 (compound 6) is a is a PROTAC protein degrader targeting EZH2 with an IC50 of 15.00 nM. PROTAC EZH2 Degrader-19 induces strong degradation of all PRC2 subunits (EZH2, SUZ12, EED, RbAp48) in a concentration- and time-dependent manner.PROTAC EZH2 Degrader-19 exhibits antiproliferative effects in cancer cells.PROTAC EZH2 Degrader-19 can be used for the research of cancer.
-
cis-VZ185
0 ImagesCat. No.: HY-114322ACAS No.: 2306193-98-4cis-VZ185 serves as a non-degradative control and inactive analog of VZ185 (HY-114322), a dual-target BRD7/BRD9 degrader PROTAC. cis-VZ185 exerts antiproliferative activity against epithelioid sarcoma cells only at high concentrations. cis-VZ185 induces morphological changes in osteosarcoma cells. cis-VZ185 can be used in studies related to epithelioid sarcoma.
